The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus

Exclusion Criteria

• •Any disease that limits life expectancy under 1 year
• •Subject for another clinical trial within the past 2 months
• •Under 20 years old or over 80 years old
• •Pregnant women
• •Lactating women
• •Drug abuser
• •Type 2 DM treated by recombinant insulin
• •Diagnosis of Type 1 DM, MODY, or secondary DM
• •HbA1c ≥12% or HbA1c \<6.5% at diagnosis
• •Previous treatment with any SGLT2 inhibitor
• •Renal dysfunction (eGFR-CKD-EPI \<30ml/min/1.73m\^2)
• •Chronic cystitis and/or recurrent genitourinary tract infections (3 or more in the last year)
• •Unexplained hematuria at baseline study
• •Systolic BP \>180mmHg or diastolic BP \>100mmHg at baseline study
• •Systolic BP \<95mmHg at baseline study
• •Previous treatment with AF ablation
• •Acute cardiovascular event \[e.g., stroke, acute coronary syndrome (ACS), revascularization, decompensated HF, sustained ventricular tachycardia, return of spontaneous circulation (ROSC)\] \<8 weeks prior to baseline study
• •Severe valvular disease or have prosthetic valve
• •Treatment with chronic oral steroid (\>30 consecutive days) at a dose equivalent to oral prednisolone ≥10mg/d, within the past 1 month
• •History of any malignancy within 5 years
• •Clinically profound hepatic dysfunction
• •Clinically uncontrolled thyroid dysfunction
• •Patients incapable of completing the trial due to any severe medical condition by clinical decision
• •Patients with poor compliance (defined as 80 - 120%), except for reasonable situations judged by physician